MBX-500, a Hybrid Antibiotic with In Vitro and In Vivo Efficacy against Toxigenic Clostridium difficile

Clostridium difficile infection (CDI) causes moderate to severe disease, resulting in diarrhea and pseudomembranous colitis. CDI is difficult to treat due to production of inflammation-inducing toxins, resistance development, and high probability of recurrence. Only two antibiotics are approved for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Butler, Michelle M., Shinabarger, Dean L., Citron, Diane M., Kelly, Ciarán P., Dvoskin, Sofya, Wright, George E., Feng, Hanping, Tzipori, Saul, Bowlin, Terry L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2012
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3421853/
https://ncbi.nlm.nih.gov/pubmed/22733075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00508-12
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados